3-tert-butyl-2-imino-5,5-diphenylimidazolidin-4-one | 56954-65-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-tert-butyl-2-imino-5,5-diphenylimidazolidin-4-one
• 英文别名: 2-amino-3-tert-butyl-5,5-diphenyl-3,5-dihydro-imidazol-4-one；4H-Imidazol-4-one, 2-amino-3-(1,1-dimethylethyl)-3,5-dihydro-5,5-diphenyl-；2-amino-3-tert-butyl-5,5-diphenylimidazol-4-one
• CAS: 56954-65-5
• 化学式: C₁₉H₂₁N₃O
• 分子量: 307.395
• InChiKey: KSYIRRMUIPTGLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-tert-butyl-5,5-diphenyl-2-thioxo-imidazolidin-4-one 在 叔丁基过氧化氢 、 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 生成 3-tert-butyl-2-imino-5,5-diphenylimidazolidin-4-one
  参考文献：
  名称：

  Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents

  摘要：

  Given the threat of drug resistance, there is an acute need for new classes of antimalarial agents that act via a unique mechanism of action relative to currently used drugs. We have identified a set of druglike compounds within the Tres Cantos Anti-Malarial Set (TCAMS) which likely act via inhibition of a Plasmodium aspartic protease. Structure-activity relationship analysis and optimization of these aminohydantoins demonstrate that these compounds are potent nanomolar inhibitors of the Plasmodium aspartic proteases PM-II and PM-IV and likely one or more other Plasmodium aspartic proteases. Incorporation of a bulky group, such as a cyclohexyl group, on the aminohydantion N-3 position gives enhanced antimalarial potency while reducing inhibition of human aspartic proteases such as BACE. We have identified compound 8p (CWHM-117) as a promising lead for optimization as an antimalarial drug with a low molecular weight, modest lipophilicity, oral bioavailability, and in vivo antimalarial activity in mice.

  DOI：

  10.1021/ml400412x

文献信息

• Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
  申请人：Albert Jeffrey

  公开号：US20090176850A1

  公开（公告）日：2009-07-09

  This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有下面的结构式I的新化合物及其药学上可接受的盐、组合物和使用方法。这些新化合物可用于治疗或预防认知障碍、阿尔茨海默病、神经退行性疾病和痴呆症。
• NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER S DISEASE, NEURODEGENERATION AND DEMENTIA
  申请人：Astra Zeneca AB

  公开号：EP1954682A1

  公开（公告）日：2008-08-13
• [EN] NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA<br/>[FR] NOUVEAUX COMPOSES 2-AMINO-IMIDAZOLE-4-ONE ET LEUR UTILISATION DANS LA FABRICATION D'UN MEDICAMENT DESTINE A ETRE UTILISE DANS LE TRAITEMENT D'UNE DEFICIENCE COGNITIVE, LA MALADIE D'ALZHEIMER, LE NEURODEGENERESCENCE ET LA DEMENCE
  申请人：ASTRAZENECA AB

  公开号：WO2007058601A1

  公开（公告）日：2007-05-24

  [EN] This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
  [FR] L'invention concerne de nouveaux composés présentant de formule structurelle (I) et leurs sels pharmaceutiquement acceptables, leurs compositions et leurs procédés d'utilisation. Les nouveaux composés de l'invention sont utilisés dans le traitement ou la prophylaxie d'une déficience cognitive, de la maladie d'Alzheimer, de la neurodégénerescence et de la démence.
• Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents
  作者：Marvin J. Meyers、Micky D. Tortorella、Jing Xu、Limei Qin、Zhengxiang He、Xingfen Lang、Wentian Zeng、Wanwan Xu、Li Qin、Michael J. Prinsen、Francis M. Sverdrup、Christopher S. Eickhoff、David W. Griggs、Jonathan Oliva、Peter G. Ruminski、E. Jon Jacobsen、Mary A. Campbell、David C. Wood、Daniel E. Goldberg、Xiaorong Liu、Yongzhi Lu、Xin Lu、Zhengchao Tu、Xiaoyun Lu、Ke Ding、Xiaoping Chen

  DOI：10.1021/ml400412x

  日期：2014.1.9

  Given the threat of drug resistance, there is an acute need for new classes of antimalarial agents that act via a unique mechanism of action relative to currently used drugs. We have identified a set of druglike compounds within the Tres Cantos Anti-Malarial Set (TCAMS) which likely act via inhibition of a Plasmodium aspartic protease. Structure-activity relationship analysis and optimization of these aminohydantoins demonstrate that these compounds are potent nanomolar inhibitors of the Plasmodium aspartic proteases PM-II and PM-IV and likely one or more other Plasmodium aspartic proteases. Incorporation of a bulky group, such as a cyclohexyl group, on the aminohydantion N-3 position gives enhanced antimalarial potency while reducing inhibition of human aspartic proteases such as BACE. We have identified compound 8p (CWHM-117) as a promising lead for optimization as an antimalarial drug with a low molecular weight, modest lipophilicity, oral bioavailability, and in vivo antimalarial activity in mice.